---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-238857"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2022-09-06T23:59:59+00:00"
generated_at: "2026-06-23T15:33:15.615322+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Amneal appoints Gustavo Pesquin as EVP, Chief Commercial Officer – Specialty

## Summary
- Pesquin joins from Sanofi, where he was North America Head for General Medicines.
- Base salary $525,000; target annual bonus 60% of base salary; RSU grant of $1,000,000 vesting over 4 years.
- Severance: 150% of base salary plus pro-rata bonus and 18 months benefits if terminated without cause or for good reason.
- Effective September 6, 2022.

## SEC filing metadata
- accession: 0001193125-22-238857
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2022-09-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000119312522238857/0001193125-22-238857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000119312522238857/d385461d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-238857
- JSON: https://secwatch.observer/filing/0001193125-22-238857.json
- Plain text: https://secwatch.observer/filing/0001193125-22-238857.txt

## Key facts
- Executive change
  Gustavo J. Pesquin was appointed as Executive Vice President and Chief Commercial Officer – Specialty at Amneal Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Executive Vice President and Chief Commercial Officer – Specialty
  source text: On September 1, 2022, the Board of Directors (the “ Board ”) of Amneal Pharmaceuticals, Inc. (the “ Company ”) appointed Gustavo J. Pesquin as the Company’s Executive Vice President and Chief Commercial Officer – Specialty, effective September 6, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000119312522238857/0001193125-22-238857-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.